ArticlemSystems2021
IS
Article in mSystems, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 58 citations in OpenAlex.
- Genomic characterization and global lineage-plasmid context of aOne health (Amsterdam, Netherlands) · 2026Article
- Outbreak and dissemination of the international high-risk NDM-5-producingZoological research · 2026Article
- Genetic and Phenotypic Characterization of aAntibiotics (Basel, Switzerland) · 2026Article
- Plasmid-resolved genomics and machine learning-assisted profiling revealFrontiers in microbiology · 2026Article
- Acupuncture modulates the microbiota-gut-brain axis to treat irritable bowel syndrome: a mechanistic exploration.Frontiers in neuroscience · 2026Review
- Molecular Epidemiology and Multilevel Drug Resistance Mechanisms ofInfection and drug resistance · 2026Review
- Article
- Emergence of carbapenem-resistantMicrobiology spectrum · 2025Article
- Genomic characterization and global relatedness of multidrug-resistant Salmonella Goldcoast ST2529.BMC genomics · 2025Article
- Co-resistance and plasmid-mediated co-dissemination of florfenicol and azithromycin resistance in non-O157 Shiga toxin-producing Escherichia coli from cattle in Xinjiang, China.BMC microbiology · 2025Article
- Fosfomycin-resistantJAC-antimicrobial resistance · 2025Article
- ISiScience · 2025Article
- Evolution, dissemination, and genetic dynamics of the carbapenem resistance geneFrontiers in cellular and infection microbiology · 2025Article
- The global prevalence, formation, and evolutionary inference of bacteria co-carrying theFrontiers in microbiology · 2025Article
- Characterization ofFrontiers in microbiology · 2025Article
- Emergence and transmission of Carbapenem-resistantFrontiers in veterinary science · 2025Article
- Genomic epidemiology of antimicrobial resistance determinants in Chinese swine farmFrontiers in microbiology · 2025Article
- Clonal dissemination of carbapenem-resistant ST477Frontiers in cellular and infection microbiology · 2025Article
- Emergence of NDM-1 on IncR-IncFIA (HI1) plasmid in carbapenem-resistantFrontiers in microbiology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Carbapenem-resistant Enterobacteriaceae are some of the most important pathogens responsible for nosocomial infections, which can be challenging to treat. The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.